Copyright #ERS Journals Ltd 2003
European Respiratory Journal
ISSN 0903-1936
Eur Respir J 2003; 22: 931–936
DOI: 10.1183/09031936.03.00038303
Printed in UK – all rights reserved
Longitudinal changes in the nature, severity and
frequency of COPD exacerbations
G.C. Donaldson, T.A.R. Seemungal, I.S. Patel, S.J. Lloyd-Owen, T.M.A. Wilkinson, J.A. Wedzicha
Longitudinal changes in the nature, severity and frequency of COPD exacerbations.
G.C. Donaldson, T.A.R. Seemungal, I.S. Patel, S.J. Lloyd-Owen, T.M.A. Wilkinson,
J.A. Wedzicha. #ERS Journals Ltd 2003.
ABSTRACT: Exacerbations are an important feature and outcome measure in chronic
obstructive pulmonary disease (COPD), but little is known about changes in their
severity, recovery, symptom composition or frequency over time.
In this study 132 patients (91 male; median age 68.4 yrs and median forced
expiratory volume in one second (FEV1) 38.4% predicted) recorded daily symptoms and
morning peak expiratory flow.
Patients were monitored for a median of 918 days and 1,111 exacerbations were
identified. Patients with severe COPD (Global Initiative for Chronic Obstructive Lung
Disease (GOLD) category III, n=38) had an annual exacerbation frequency of
3.43?yr-1, 0.75?yr-1 higher than those with moderate COPD (GOLD II, n=94).
Exacerbation frequency did not change significantly during the study. At exacerbation
onset, symptom count increased to 2.23, relative to a baseline of 0.36 set 8–14 days
previously, and this increase rose by 0.05?yr-1. Recovery to baseline levels in symptoms
and FEV1 took longer (0.32 and 0.55 days?yr-1). Sputum purulence at exacerbation
became more prevalent over time by 4.1%?yr-1 from an initial value of 17%.
The results of this study suggest that over time, individual patients have more
symptoms during exacerbations, with an increased chance of sputum purulence and
longer recovery times.
Eur Respir J 2003; 22: 931–936.
Patients with chronic obstructive pulmonary disease (COPD)
are prone to exacerbations that are an important determinant
of health-related quality of life, morbidity and mortality
[1, 2]. Exacerbations are characterised by acute worsening of
symptoms, increased airway inflammation and physiological
deterioration [3]. They have become an important outcome
measure in the study of therapy in COPD. Recently, two
studies have suggested that exacerbations may affect disease
progression by accelerating the forced expiratory volume in
one second (FEV1), a decline characteristic of COPD [4, 5].
The authors have estimated that exacerbations may account
for y25% of the FEV1 decline in COPD [5]. However, to date
there is no information about the history of exacerbations in
COPD patients.
The authors have also previously shown that a significant
number of exacerbations do not recover to baseline levels in
symptoms and/or lung function [6] and it is possible that this
nonrecovery may be the mechanism by which exacerbations
contribute to lung function decline. Alternatively, the impact
of exacerbations may increase over time, resulting in greater
airway inflammation, which contributes to the accelerated
FEV1 decline. Previously, the authors have shown that
exacerbation length (recovery) is related to the magnitude of
the acute deterioration (severity) in lung function and
symptoms at exacerbation, with exacerbation impact defined
by the combination of the severity and the length of recovery
[6]. However, there is no previous data available as to how
exacerbation impact changes over time.
This study followed 132 COPD patients over 6 yrs and
collected data on 1,111 exacerbations. Patients recorded on
Academic Unit of Respiratory Medicine,
St. Bartholomew9s and Royal London School
of Medicine and Dentistry, London, UK.
Correspondence: J.A. Wedzicha
Academic Unit of Respiratory Medicine
Dominion House
St. Bartholomew9s Hospital
London EC1A 7BE
UK
Fax: 44 2076018616
E-mail: j.a.wedzicha@gmul.ac.uk
Keywords: Chronic obstructive pulmonary
disease
cohort studies
exacerbations
Received: April 7 2003
Accepted after revision: September 3 2003
This study was supported by the British Lung
Foundation and GlaxoSmithKline.
diary cards daily peak expiratory flow (PEF) and/or spirometry and increase in symptoms. The authors used a set of
indices, based on previous descriptions of the time course of
symptoms and lung function associated with an exacerbation
[6], which divided an exacerbation into a prodromal or baseline period, onset and recovery. The objective of the current
study was to investigate whether the frequency, symptom
composition and indices of severity and recovery of exacerbations changed over time.
Methods
Patients
A total of 177 patients with COPD were recruited from the
outpatients dept of the London Chest Hospital in the first
5 yrs of this 6-yr study. In the first year, 99 patients were
recruited consecutively and from then on those who subsequent withdrew or died were replaced. The recruitment
criteria were an FEV1 v70% predicted from sex, age and
height, a FEV1/forced vital capacity (FVC) ratio v70%,
b2 agonist reversibility v15% and/or v200 mL, the absence of
asthma, bronchiectasis, bronchial carcinoma or other significant respiratory disease, and a willingness to participate in
a long-term study. Of these 177 patients, 132 were selected for
this analysis on the basis that they had recorded diary card
data on a minimum of 365 days. The reasons for 45 patients
failing to record sufficient data were withdrawal, death or
932
G.C. DONALDSON ET AL.
inadequate completion of diary cards, combined with late
enrollment. The 132 patients did not differ significantly from
the 45 excluded patients in any of the characteristics reported
in table 1, except for a slightly lower PEF (152 versus 181 L?min-1;
Wilcoxon p=0.0179) and FVC (2.14 versus 2.44 L; p=0.039).
This cohort has been the subject of previous publications,
which investigated the relationship of COPD exacerbations to
quality of life [1], inflammatory markers [3], lung function
decline [5], time course of symptoms and lung function [6],
respiratory viruses [7], fibrinogen [8] and bacterial colonisation [9]. This is the first longitudinal analysis on the history of
exacerbations with 6 yrs of data.
Enrollment
At recruitment, measurements were made of FEV1, FVC
and PEF by rolling seal spirometer (Sensor Medic Corp.,
Yorba Lindo, CA, USA), reversibility to 400 mg inhaled
salbutamol and arterialised ear lobe blood gases (model 278
Blood Gas Analyzer; Ciba-Corning, Medfield, MA, USA)
[10]. A history was taken of smoking habits (years of smoking, current smoking status). Patients were asked about their
symptoms of dyspnoea, sputum production, wheeze and
cough. The patients were also asked about their long-term
inhaled and oral steroid use. The study had ethics approval
from the Ethics Committee of the East London and City
Health Authority and patients provided written informed
consent.
Monitoring and exacerbation
The patients were asked to record postmedication PEF
(Mini-Wright Clement Clark International Ltd, Harlow, UK)
and any increase over their normal, stable condition in
symptoms of dyspnoea, sputum purulence or sputum volume
(major symptoms) and colds (nasal discharge/congestion),
wheeze, sore throat, cough (minor symptoms) on diary cards
each morning. A total of 35 randomly selected patients also
Table 1. – Characteristics of the 132 chronic obstructive
pulmonary disease patients in the study, and the 35 who
recorded forced expiratory volume in one second (FEV1),
measured at recruitment
Patients n
Age yrs
FEV1 L
FEV1 % predicted
FEV1 % reversibility
FVC L
FEV1/FVC %
PEF L?min-1
Pa,O2 mmHg
Pa,CO2 mmHg
Smoking yrs
Sex males
Chronic dyspnoea
Chronic wheeze
Chronic cough
Chronic sputum production
History of smoking
Smoking at recruitment
Inhaled steroids
Oral steroids
132
68.4 (62.5–73.7)
0.99 (0.74–1.3)
38.4 (27.0–49.9)
5.4 (0–12.6)
2.45 (1.82–2.93)
42.3 (33.2–53.1)
181 (139–250)
68.4 (62–73)
44.2 (41–48)
42 (31–50)
68.9
48.5
32.6
47.0
53.8
95.4
31.1
90.2
9.0
35
65.1 (60.7–73.6)
1.08 (0.77–1.4)
36.0 (25.4–50.0)
6.1 (0–12.8)
2.6 (1.99–2.90)
45.3 (33.1–53.7)
240 (162–300)
68.4 (62–75)
44.7 (42–50)
40 (27–46)
88.6
54.3
34.3
42.9
45.7
94.3
34.2
85.7
14.2
Data are presented as median (interquartile range) or % of patients.
FVC: forced vital capacity; PEF: peak expiratory flow; Pa,O2: arterial
oxygen tension; Pa,CO2: arterial carbon dioxide tension.
measured daily FEV1 and FVC using a hand-held spirometer
(Micro Medical Ltd, Chatham, Kent, UK). Exacerbation
onset was taken as the first of two or more consecutive days
with increase in either two or more major symptoms, or any
one major symptom plus any minor symptoms [1, 3, 5, 6].
Symptoms were disregarded in identifying onset if recorded
continuous in the 5-day period preceding a suspected exacerbation onset. Two subjects separately identified exacerbations
(at clinic visits and at data entry) and then later resolved
disagreements in diagnosis and timing. Exacerbations for
which no or insufficient diary-card symptoms were recorded
by the patient, were on occasion identified by hospital admission for an acute exacerbation of COPD or by questioning at
clinic visits. Patients with increased symptoms were encouraged to contact the clinical team by telephone, and were seen
prior to treatment generally within 48 h. The exacerbations
seen by the clinical team were classified as "reported
exacerbations" with those unseen termed "unreported exacerbations". Records were kept of hospitalisation throughout,
and from November 1996 onwards, records were available of
the date of initiation and type of treatment prescribed to
patients both at the authors9 clinic and also that prescribed by
the patient9s general practitioner (GP).
Statistical analysis
Data are presented as mean (SD) or median (interquartile
range (IQR)) and comparisons performed by unpaired t-test,
Wilcoxon matched-paired sign-rank test or a Chi-squared
test, as appropriate. Differences in exacerbation frequency
between groups were estimated using generalised linear models
assuming a poisson distribution in the frequency, and thus
95% confidence intervals (95% CI) are reported rather than
IQR.
Indices of exacerbation severity
Exacerbation severity with respect to lung function and
symptom count (the sum of the binary coded presence or
absence of seven respiratory symptoms) was assessed over a
51-day period. Baseline was taken as the mean of a parameter
over days 14–8 preceding exacerbation onset, as no significant
changes in lung function and symptoms were seen over this
time period. The change in any parameter associated with
exacerbation was taken as the difference between baseline and
the day of onset. Recovery was the time from onset for a 3day moving average to equal or exceed the baseline. A moving
average was used to avoid false early recoveries when lung
function improved for just a single day, but then remained
below baseline for a few more days. The authors analysed
recovery from exacerbation at 35 days because in most
clinical studies a patient not having an exacerbation for 4–6
weeks would be considered stable. Exacerbation nonrecovery
was taken as recovery taking w35 days [6].
To assess changes over time of these indices, cross-sectional,
generalised linear models were fitted using the xtgee command
in Stata 5.0 (Stata Corporation, Texas, USA). These models
examine time variations independently of cross-section variations in panel data [11]. The distribution of the dependent
variable was specified after inspecting histograms of the data
and the independent variable was time in years.
Exacerbation frequency and symptom composition
Each patient was considered to have started on the same
day (day 1=November 1, 1995), whether enrolled on or after
933
LONGITUDINAL CHANGES IN COPD EXACERBATIONS
that date, to avoid bias from patients recruited later during
the study who may have had very high or low exacerbations
frequencies. The subsequent 6 yrs were then divided into 24
quarter-yr periods. Within each period, the number of exacerbations was divided by the number of patients involved, and
multiplyed by four, to give an annual exacerbation frequency.
The symptom percentage was calculated by dividing the
number of exacerbations with a given symptom by the total
number of exacerbations and multiplying by 100. Linear
regression was then used to assess time trends in frequency
and symptoms. Quarter year periods were chosen as a compromise between year long periods, in which the number of
patients at the start and end of the year would differ
markedly, and between month long periods in which too
few exacerbations would occur to sensibly calculate the symptom percentages. The analysis was repeated with allowance
for seasonality, as the findings could potentially be biased by
enrollment during the winter or withdrawal just before winter
when exacerbations are more common. The exacerbation
frequency was calculated as above, but without aligning the
start dates of each patient. Sine and cosine terms with a year
period, in addition to the trend term, were then fitted by the
regression technique described above.
The authors chose not to analyse changes over time in the
interval between exacerbations using cross-sectional models,
since interval data will over estimate exacerbation frequency
towards the end of the study period, when completed intervals
for patients with infrequent exacerbations are less likely to be
available relative to patients with frequent exacerbations.
With the approach adopted by the authors, it was not sensible
to analyse differences between groups, such as smoking status
or drug therapy, as too few patients would be available in the
later stages of the study, nor was the study designed with
these analyses in mind.
or the patient9s GP, relative to the prior year, did not change
over time (0.93; 95% CI: 0.84–1.03; p=0.149).
The median exacerbation rate was 2.52 (IQR: 1.34–3.93)
exacerbations?yr-1. The exacerbation frequency was 3.43?yr-1
(95% CI: 2.7–4.2), 0.75?yr-1 (0.08–1.43) higher (p=0.029) in
patients (n=38) with severe COPD (FEV1 v30% pred and
FEV1/FVC v70% pred; Global Initiative for Chronic
Obstructive Lung Disease (GOLD) category III), compared
with those (n=94) with moderate COPD (FEV1 o30% pred
and v80% pred and FEV1/FVC v70% pred; GOLD category
II) whose frequency was 2.68 (2.35–3.01). The FEV1 in the
two groups were 0.67 L (SD 0.14) and 1.22 L (0.4),
respectively (pv0.001). There was no significant difference in
exacerbation frequency between GOLD IIA and GOLD IIB.
There was no significant difference in the exacerbation
frequency of those 35 patients who recorded FEV1, and
FVC (3.17?yr-1; 95% CI: 2.4–3.9) and the other 97 patients
(2.80?yr-1; 2.5–3.1; p=0.286). There was no significant difference in exacerbation frequency between the 64 patients who
withdrew early from the study (median 3.06?yr-1; 2.4–3.8) and
those who were still participating at the end of the study in
November 2001 (2.7?yr-1; 2.3–3.1; p=0.307). There was also no
difference in exacerbation frequency between the 19 patients
who died and the other 113 patients (2.77 versus 2.92?yr-1;
p=0.724).
Annual exacerbation frequency for all 132 patients remained
constant during the study, changing by only -0.025?yr-1 (95%
CI: -0.065–0.015; p=0.208) from a starting value of 2.88?yr-1.
The exacerbation frequency was also constant if allowance
was made for seasonality (-0.025?yr-1; -0.054–0.003; p=0.080),
although there were significant winter peak to summer trough
changes of 1.28 exacerbations?yr-1 (pv0.001). Over time, symptoms at exacerbation of both sputum purulence and volume
rose by 4.12%?yr-1 (p=0.004) and 5.25%?yr-1 (p=0.001) respectively, whilst wheeze fell by 2.8%?yr-1 (p=0.004) (fig. 1). There
was no significant change in the other symptoms (table 2).
Results
Patients
The 132 patients (91 male, 31 female) studied had moderateto-severe COPD (table 1). Of these, 119 patients took inhaled
steroids daily (1.53 (SD 1.1) mg?day-1 beclomethasone equivalents) and 12 patients took a mean 5.91 (3.0) mg?day-1 of oral
prednisolone; 10 patients used both oral and inhaled steroids.
The subgroup of 35 (31 male, four female) patients who
recorded daily FEV1 and FVC were similar to the others for
the characteristics reported in table 1, except they had a
higher PEF (p=0.001) and a higher percentage of males
(p=0.003).
Exacerbation frequency, changes over time
The patients participated in the study for a median of 918
(IQR: 666–1.365) days. During the 6 yrs of the study, seven of
the 132 patients had no exacerbations and eight patients had
just one. There were a total of 1,111 exacerbations of which
971 (87%) were identified from the symptom data recorded by
the patients on their diary cards, 123 (11%) by questioning
about symptoms at clinic, six by hospital admission alone,
eight by treatment by the authors or GP alone, and three were
recorded as an exacerbation but other data lost. In total,
511 (46.0%) of all exacerbations were reported and seen by
the clinical team. The odds ratio of an exacerbation being
reported to the authors clinic team, was 0.84 (95% CI:
0.78–0.91; pv0.001) relative to the preceding year. However,
the odds ratio of an exacerbation being treated by the authors
Exacerbation severity, changes over time
Table 3 shows estimates of the annual change in the timecourse indices and their value at the start of the study in
November 1995. At the study start, symptom count at
baseline was estimated as 0.36 and rose to 2.23 at exacerbation onset. Over time, symptom count did not rise significantly during the baseline period or at exacerbation onset, but
their difference did increase by 0.05?yr-1 (p=0.047). FEV1 at
baseline declined significantly by -34.5 mL?yr-1 (pv0.001) but
there was no change over time in FEV1 at exacerbation onset.
FVC did not change significantly over time at baseline or
Table 2. – Changes over time in the frequency of symptoms
reported at exacerbation
Symptom
Dyspnoea
Sputum purulence
Sputum volume
Cold#
Wheeze
Sore throat
Cough
Starting
value %
Annual
change %?yr-1
95% CI
p-value
60
17
34
31
38
13
30
1.30
4.12
5.25
-1.77
-2.87
-0.38
-0.81
-1.7–4.3
1.4–6.8
2.2–8.2
-3.7–0.02
-4.7–-1.0
-1.7–0.9
-2.3–0.7
0.383
0.004
0.001
0.073
0.004
0.556
0.281
The starting value estimates the percentage of exacerbations with a
particular symptom had they all occurred at the start of the study and
the annual change gives how this percentage changed over time. CI:
confidence interval. #: nasal congestion/discharge.
934
G.C. DONALDSON ET AL.
Table 3. – Changes in indices of exacerbation baseline, recovery and nonrecovery over time
Baseline
Symptom count#
PEF L?min-1
FEV1 mL
FVC mL
At exacerbation onset
Symptom count
PEF L?min-1
FEV1 mL
FVC mL
Recovery time
Symptom count day
PEF day
FEV1 day
Nonrecovery w35 days
Symptom count
PEF
FEV1
FVC
Starting value
Annual change
95% CI
p-value
Exacerbations n
Subjects n
0.36
234
1034
1856
-0.012
-2.8
-34.5
18.0
-0.04–0.01
-4.3–-1.3
-52– -16
-53–90
0.352
0.000
0.000
0.623
1045
1043
221
199
123
123
32
31
2.23
217
966
1743
0.034
-0.81
-17.8
39.6
-0.013–0.08
-2.1–0.57
-36–0.2
-7.4–8.6
0.153
0.249
0.052
0.099
1045
1011
212
190
123
123
32
31
8.4
7.8
6.1
0.32
-0.07
0.55
0.20–0.44
-0.18–0.03
0.26–0.85
0.000
0.163
0.000
945
922
199
122
122
31
1.00}
0.95}
1.12}
1.42}
0.88–1.14
0.85–1.07
0.81–1.53
0.84–2.39
0.994
0.412
0.493
0.185
1045
1043
221
199
123
123
32
31
A normal distribution was assumed for data at baseline and at exacerbation onset. A poisson distribution was assumed for data on recovery, and a
binomial distribution for nonrecovery. CI: confidence interval; PEF: peak expiratory flow; FEV1: forced expiratory volume in one second; FVC:
forced vital capacity. #: symptom count the sum of the seven respiratory symptoms recorded each day, with presence/increased scored 1 and absence
0; }: the change from 1 yr to next in nonrecovery, data presented as odds ratio.
onset. At baseline PEF fell by 2.7 L?min-1?yr-1 (pv0.001) but
PEF did not change at exacerbation onset over time (p=0.249).
Recovery in FEV1, FVC and symptom count from exacerbation took significantly longer each year, by 0.55, 0.85 and
0.32 days?yr-1, respectively (all pv0.001). No change was seen
in recovery of PEF. Similar results were found for exacerbations that were untreated, with recovery respectively taking
0.34, 1.39 and 0.39 days?yr-1 longer (all pv0.013). Again,
changes in PEF recovery were nonsignificant.
Complete recovery to baseline levels did not always take
place: 121 of 1,043 (11.6%) never recovered in PEF, 100 of
1,045 (9.6%) in symptom count, 22 of 221 (10.0%) in FEV1
and 15 of 199 (7.5%) in FVC. Table 3 also shows that there
was no significant change in the number of exacerbations not
recovering within 35 days over time.
Drug treatment and hospitalisation, changes over time
During the whole study, there were 65 hospitalisations for
acute exacerbation of COPD, representing 5.9% of the 1,111
exacerbations. The odds ratio of hospitalisation increased by
1.26 each yr (95% CI: 1.084–1.459; p=0.002). The median
length of stay in hospital was 11 days (IQR: 7–15 days) and
did not change over time. Data collected over the last 5 yrs of
the study showed that of 918 exacerbations, 223 (24.3%) were
treated with oral steroids and 525 (57.1%) with antibiotics.
There was a significant increase in treatment of exacerbations
with oral steroids, as the odds ratio for treatment was 1.12
(95% CI: 1.00–1.25; p=0.051) relative to the previous year, but
a fall in treatment with antibiotics, as the odd ratio was 0.91
(0.82–1.00; p=0.052).
Discussion
This is the first study to examine the history of exacerbations in patients with moderate-to-severe COPD. Patients
were monitored with daily diary cards, recording daily
symptoms, peak flow and/or spirometry. No previous study
has prospectively collected such an extensive and detailed
data set on exacerbations in a COPD patient group. The main
findings were that over time exacerbation recovery took
longer and symptoms at exacerbation of sputum purulence
became more frequent.
In this study, exacerbations were identified according to
criteria previously described and used consistently in all the
authors9 studies [l, 3, 5, 6]. Patients were encouraged to report
exacerbations to the study team and about half of the
exacerbations were reported and seen by the authors9 physicians. Most studies of COPD exacerbation have depended
on data involving healthcare utilisation, and so have included
only exacerbations reported to healthcare professionals. The
authors have previously shown that there are similarities
between reported and unreported exacerbations in symptom
composition, physiological and symptom changes and recovery [1, 6]. These similarities may be due to under-reporting of
exacerbation as COPD patients become accustomed to
frequent symptom changes or experience depression [12]
that may lead them to accept their situation. In the current
study the authors have included both reported and unreported exacerbations and thus have a complete set of
exacerbation data. The median exacerbation frequency in
this 6-yr study is higher than in other studies [4, 13] at 2.52
events?patient-1?yr-1 and this reflects the contribution of these
unreported exacerbations.
The authors found no overall increase in exacerbation
frequency over the 6-yr study period. There is little information in the literature about long-term trends in exacerbation
frequency. KANNER et al. [4] reported an increase in the
number of lower respiratory tract infections over time in
continuous smokers but no change was found in sustained
quitters. In this study, 41 patients (31%) were current smokers
and so an intermediate finding of no increase would be
expected. Exacerbation frequency is widely thought to increase over time because exacerbations are more frequent in
severe COPD. GREENBERG et al. [15] have reported that
respiratory illnesses are more frequent (3?yr-1) in moderate
COPD than in mild COPD (1.8?yr-1). In the current study, the
authors found more exacerbations per year in patients with
935
LONGITUDINAL CHANGES IN COPD EXACERBATIONS
a) 100
Dyspnoea
80
60
40
20
0
b) 100
Sputum purulence
80
60
40
20
0
c) 100
80
Sputum volume
severe COPD (GOLD category III) than in moderate COPD
(GOLD category II), 3.4?yr-1 compared with 2.7?yr-1, respectively. The finding that there is little discernable change in
frequency over 6 yrs seems reasonable in view of the following
calculation. The difference in exacerbation frequency between
moderate and severe COPD was 0.75?yr-1, with a mean FEV1
in the two groups of 1.22 and 0.67 L, respectively, so with a
decline in FEV1 of 34.5 mL?yr-1 as in the current study,
it would take 15.9 yrs for the frequency to rise by 0.7,
equivalent to an annual rise of only 0.047 exacerbations?yr-1.
A large proportion of COPD exacerbations are triggered by
respiratory viral infections [7], but there is no evidence to date
of increased susceptibility to respiratory viral infection in
patients with COPD compared with controls [15]. This would
also help to explain the relative stability of the exacerbation
frequency over time. Additionally, the relationship between
disease severity and exacerbation frequency may not be linear
over the different severities of COPD. This study is confined
to patients with moderate-to-severe COPD. The stability of
the exacerbation frequency may also be due to treatment with
bronchodilators [16] and inhaled steroids [17, 18] as both have
been shown to have an effect on reducing exacerbation
frequency. The absence of any increase in exacerbation frequency over time could not be attributed to the early withdrawal or death of those patients with a high exacerbation
frequency, as no difference was found between the median
exacerbation rate of those who left the study early or who
remained for the duration. In the current study, the authors
found more hospitalisations over time. Others have also
found that hospital admissions and readmissions are more
common in patients with more severe COPD [15]. As exacerbation frequency did not increase much over time, this
increase in hospital admissions possibly reflects the greater
impact of an exacerbation on a patient whose health has
become poorer as they have grown older, and whose increased
risk of dying makes the physician more likely to admit.
An important finding in this study is that exacerbation
recovery for FEV1, FVC and symptom count was significantly longer each year. These changes occurred despite an
increasing use of oral corticosteroid therapy at exacerbation
that has been shown to hasten lung function recovery [19, 20]
but could have been contributed to by the decreased use of
antibiotics. The authors have previously shown that symptom
count and lung function changes at exacerbations are related
to exacerbation recovery time [3]. The authors have also
shown that exacerbations triggered by viral infections have
higher symptom scores and are associated with an increased
exacerbation length and recovery [7, 21]. Exacerbations
triggered by respiratory viruses or symptomatic colds have
been shown to have increased airway and systemic inflammatory markers at exacerbation onset, compared with those
where no virus was detected or no cold was reported [3, 7, 8,
21]. Thus, more severe exacerbations are associated with
increased airway and systemic inflammation and as patients
with increased airway inflammation show faster FEV1 decline
[22], this mechanism may explain how exacerbation severity
affects disease progression.
The authors have recently shown that patients with lower
airway bacterial colonisation (LABC) have a history of
increased exacerbation frequency, compared with patients
without LABC, and that these patients have more exacerbations associated with purulent sputum [9]. It has been shown
that the presence and load of colonising bacteria in the lower
airway may independently modulate airway inflammation in
COPD [23]. In addition, LABC in COPD is associated with
markers of disease severity [24–27]. One of the major findings
in the present study was that, over time, exacerbations were
associated with a greater prevalence of sputum purulence and
volume. Sputum purulence is related to the detection of a
60
40
20
0
0
6
12
Quarter yr
18
24
Fig. 1. – Percentage of exacerbations of a) dyspnoea, b) sputum
purulence, and c) sputum volume, with the patient recording a major
symptom on the day of onset, over time. Patients were assumed to
have started the study on the same day. Circle size indicates the
number of exacerbations recording in that quarter-year.
bacterial pathogen at exacerbation [28] and this data therefore
suggest that over time, exacerbations may become more
severe as they are associated with increasing bacterial loads
and airway inflammation. This is also consistent with the
finding that antibiotics were more effective at exacerbation in
more severe patients [29].
The authors have also previously reported that COPD
exacerbation may not recover to baseline [6] and in this study
y10% of the exacerbation did not recover to baseline of either
symptom count or peak flow. However, the authors did not
find more nonrecovery over time and thus it seems that the
decline in lung function is not specifically associated with
incomplete recovery at exacerbation.
Exacerbations are an important determinant of health
936
G.C. DONALDSON ET AL.
status and morbidity in chronic obstructive pulmonary
disease. This study suggests that the increasing morbidity
from exacerbation is due mainly to the increase in the
duration of the exacerbation, rather than to an increase in
frequency. Strategies aimed at reducing exacerbation duration, possibly by early treatment, need to be developed and
may have important benefits to these chronic obstructive
pulmonary disease patients.
Acknowledgements. The authors would like to
thank M. Roland, A. Bhowmik and S. Leedham
for assistance with data collection.
14.
15.
16.
17.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Seemungal TAR, Donaldson GC, Paul EA, Bestall JC,
Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality
of life in patients with chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 1998; 157: 1418–1422.
Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes
following acute exacerbation of severe chronic obstructive
lung disease. Am J Respir Crit Care Med 1996; 154: 959–967.
Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA.
Relation of sputum inflammatory markers to symptoms and
lung function changes in COPD exacerbations. Thorax 2000;
55: 114–120.
Kanner RE, Anthonisen NR, Connett JE. Lower Respiratory illnesses promote FEV1 decline in current smokers but
not ex-smokers with mild chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2001; 164: 358–364.
Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha
JA. The relationship between exacerbation frequency and
lung function decline in chronic obstructive pulmonary
disease. Thorax 2002; 57: 847–852.
Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ,
Wedzicha JA. Time course and recovery of exacerbations in
patients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2000; 161: 1608–1613.
Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute
exacerbations and stable chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2001; 164: 1618–1623.
Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute
exacerbations of chronic obstructive pulmonary disease are
accompanied by elevations of plasma fibrinogen and serum
IL-6 levels. Thromb Haemost 2000; 84: 210–215.
Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ,
Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of
COPD exacerbations. Thorax 2002; 57: 759–764.
Pitkin AD, Roberts CM, Wedzicha JA. Arterialised earlobe
blood gas analysis: an under used technique. Thorax 1994;
49: 364–366.
Liang K-Y, Zeger SL. Longitudinal data analysis using
generalized linear models. Biometrika 1986; 73: 13–22.
Okubadejo AA, Jones PW, Wedzicha JA. Quality of life in
patients with chronic obstructive pulmonary disease and
severe hypoxaemia. Thorax 1996; 51: 44–47.
Anthonisen NR, Manfreda J, Warren CP, Heshford EW,
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Harding GKM, Nelson NA. Antibiotic therapy in exacerbation
of chronic obstructive pulmonary disease. Ann Intern Med
1987; 106: 196–204.
Garcia-Aymerich J, Monso E, Marrades RM, et al. Risk
factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am J Respir Crit
Care Med 2001; 164: 1002–1007.
Greenberg SB, Allen MA, Wilson J, Atmar RL. Respiratory
viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;
162: 167–173.
Vincken W, van Noord JA, Greefhorst AP, et al. Improved
health outcomes in patients with COPD during 1 yr9s
treatment with tiotropium. Eur Respir J 2002; 19: 209–216.
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA,
Maslen TK. Randomised, double blind, placebo controlled
study of fluticasone propionate in patients with moderate to
severe chronic obstructive pulmonary disease: the ISOLDE
trial. BMJ 2000; 320: 1297–1303.
The Lung Health Study Research Group. Effect of inhaled
triamcinolone on the decline in pulmonary function in
chronic obstructive pulmonary disease. N Engl J Med
2000; 343: 1902–1909.
Davies L, Angus RM, Calverley PM. Oral corticosteroids in
patients admitted to hospital with exacerbations of chronic
obstructive pulmonary disease: a prospective randomised
controlled trial. Lancet 1999; 354: 456–460.
Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of
systemic glucocorticoids on exacerbations of chronic
obstructive pulmonary disease. N Engl J Med 1999; 340:
1941–1947.
Seemungal TA, Harper-Owen R, Bhowmik A, Jeffries DJ,
Wedzicha JA. Detection of rhinovirus in induced sputum at
exacerbation of chronic obstructive pulmonary disease. Eur
Respir J 2000; 16: 677–683.
Stanescu D, Sanna A, Veriter C, et al. Airways obstruction,
chronic expectoration, and rapid decline of FEV1 in smokers
are associated with increased levels of sputum neutrophils.
Thorax 1996; 51: 267–271.
Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin
Microbiol Rev 2001; 14: 336–363.
Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A.
Airway inflammation and bronchial microbial patterns in
patients with stable chronic obstructive pulmonary disease.
Eur Respir J 1999; 14: 1015–1022.
Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing
factors to bacterial colonization in chronic obstructive
pulmonary disease. Eur Resp J 1999; 13: 343–348.
Monso E, Rosell A, Bonet G, et al. Risk factors for lower
airway colonization in chronic bronchitis. Eur Resp J 1999;
13: 338–342.
Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA.
Association between airway bacterial load and markers of
airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109: 288–295.
Stockley RA, O9Brien C, Pye A, Hill SL. Relationship of
sputum colour to nature and outpatient to management of
acute exacerbations of COPD. Chest 2000; 117: 1638–1645.
Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in
chronic obstructive pulmonary disease exacerbations: a
meta-analysis. JAMA 1995; 273: 957–960.